HER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor
Tom Zhang(Memorial Sloan Kettering Cancer Center), Romel Somwar(Memorial Sloan Kettering Cancer Center)
Cited by 16
Related Papers
Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling
|Science Translational Medicine|2011|530
Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in <i>EGFR</i> -Mutant Lung Cancer
|Clinical Cancer Research|2020|381
Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers
|Journal of Thoracic Oncology|2019|97
Establishment of multiple novel patient-derived models of desmoplastic small round cell tumor enabling functional characterization of ERBB pathway signaling and pre-clinical evaluation of a novel targeted therapy approach
|bioRxiv (Cold Spring Harbor Laboratory)|2020|4
<i>RRAS</i> and <i>RRAS2</i> mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236
|bioRxiv (Cold Spring Harbor Laboratory)|2025|0